Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results

Artivion, Inc. (NYSE: AORT), a prominent company specializing in cardiac and vascular surgery solutions, has announced the release date for its fourth quarter financial results for 2025. The results are set to be disclosed on Thursday, February 12, 2026, after market hours. Following the release, Artivion will host a teleconference and live webcast at 4:30 p.m. ET to discuss the financial outcomes. The session will include a question-and-answer segment led by Pat Mackin, the Chairman, President, and CEO of Artivion.

To participate in the live teleconference, interested parties are encouraged to dial 201-689-8261 a few minutes before the scheduled start time. For those unable to attend, a replay of the teleconference will be available roughly one hour after its conclusion. This can be accessed by calling the toll-free number 877-660-6853 or 201-612-7415, using the conference number 13758212.

The webcast and its replay will be conveniently available on the Investor section of Artivion's official website, wherein attendees can also find a copy of the earnings press release containing detailed financial and statistical information for the quarter and full year.

Founded and headquartered in suburban Atlanta, Georgia, Artivion is dedicated to innovating straightforward solutions that tackle significant challenges faced by cardiac and vascular surgeons in treating aortic diseases. The company’s product lineup includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable human tissues, with its offerings marketed in over 100 countries worldwide. For further updates and detailed information about Artivion, stakeholders can visit www.artivion.com.

Artivion Inc. (NYSE: AORT) is preparing to release its fourth quarter 2025 financial results on February 12, 2026, after market hours. For investors and analysts, this event represents a crucial opportunity to gauge the company’s performance in the rapidly evolving cardiac and vascular medical device market, particularly given the focus on addressing aortic diseases.

Investors should pay attention to key metrics that will likely be highlighted during the teleconference at 4:30 p.m. ET, hosted by CEO Pat Mackin. Look for updates on revenue growth, profitability margins, and sales performance in their core product lines, including aortic stent grafts and On-X mechanical heart valves. These products are critical drivers of growth, and any signals of market expansion or contraction could impact the stock's trajectory.

Moreover, Artivion operates in over 100 countries, making exposure to global market dynamics essential. Investors should remain alert to any comments on international sales performance, particularly in emerging markets where demand for advanced medical devices is growing. Additionally, future guidance on product development and upcoming launches can provide insights into potential revenue streams and long-term growth.

The teleconference offers an opportunity for a Q&A session that might unveil management's perspectives on industry trends, competitive challenges, or impending regulatory changes that could affect the business landscape. Such insights are often just as revealing as raw financial data.

With the potential volatility that surrounds earnings announcements, especially in the biotech and medical device sectors, investors should consider their risk appetite and keep an eye on post-announcement trading volumes for informed decision-making. Preparing for a range of outcomes, including uncertainty in guidance or operational challenges, can help navigate the resulting market movements effectively.